🔎 Trials Near Me

Akèy › Limfòm Burkitt › Oregon

Etid klinik pou Limfòm Burkitt nan Oregon

8 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan Oregon.

Vil nan Oregon

Tèks ofisyèl etid la (Anglè)

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT03739814

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Oregon Health and Science University ( Site 1004), Portland
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Providence Newberg Medical Center, Newberg
  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • ak 2 plis
Ap rekriteFaz 3
Laj 18 a 39 · Tout sèks · Mizajou Sep 2, 2026 · NCT03150693

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
Ap rekriteFaz 2
Laj 1 a 30 · Tout sèks · Mizajou Sep 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Oregon Health & Science University, Portland
Ap rekriteFaz 2
Laj 7 a 25 · Tout sèks · Mizajou Aug 19, 2026 · NCT05082519

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Oregon Health & Science University, Portland
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579

Study of SGR-1505 in Mature B-Cell Neoplasms

  • Oregon Health and Science University - Knight Cancer Institute, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019

Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.